Neuragen® for the relief of neuropathic pain part 2: a randomised, double-blind, placebo controlled clinical trial

INTERVENTION: Topical application of Neuragen® with different amounts of effective ingredients versus a placebo. The medicine was sprayed onto the subjects feet at the sole and on top of the feet. One time application with an 8‐hour follow‐up. CONDITION: Peripheral neuropathy ; Nervous System Diseases ; Other polyneuropathies PRIMARY OUTCOME: Foot sole pain on 11‐point numerical pain scale. 0 ‐ 10 visual analog scale was use to document pain level at 30 minutes before and after the administration of the medication, with 8‐hour follow up every hour on the hour. SECONDARY OUTCOME: Duration of pain reduction. 0 ‐ 10 visual analog scale was use to document pain level at 30 minutes before and after the administration of the medication, with 8‐hour follow up every hour on the hour. INCLUSION CRITERIA: 1. Male and female, over 21 years 2. Diagnosed neuropathic pain for more three months 3. Pain level between 3 ‐ 8 on a 0 ‐ 10 visual pain scale 4. Does not have mental and communication impairments